Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Xenetic Biosciences Inc (XBIO)

Xenetic Biosciences Inc (XBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,197
  • Shares Outstanding, K 1,542
  • Annual Sales, $ 2,500 K
  • Annual Income, $ -3,960 K
  • EBIT $ -4 M
  • EBITDA $ -4 M
  • 60-Month Beta 2.17
  • Price/Sales 2.10
  • Price/Cash Flow N/A
  • Price/Book 0.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.72
  • Number of Estimates 1
  • High Estimate -0.72
  • Low Estimate -0.72
  • Prior Year -0.78
  • Growth Rate Est. (year over year) +7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.25 +4.00%
on 03/13/25
4.12 -17.97%
on 03/05/25
-0.61 (-15.29%)
since 02/24/25
3-Month
3.25 +4.00%
on 03/13/25
4.34 -22.12%
on 01/22/25
-0.77 (-18.55%)
since 12/24/24
52-Week
2.78 +21.58%
on 08/06/24
5.20 -35.00%
on 08/05/24
-0.48 (-12.44%)
since 03/22/24

Most Recent Stories

More News
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers

XBIO : 3.38 (+0.30%)
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

XBIO : 3.38 (+0.30%)
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology...

XBIO : 3.38 (+0.30%)
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement of...

XBIO : 3.38 (+0.30%)
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications

XBIO : 3.38 (+0.30%)
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

Collaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications

XBIO : 3.38 (+0.30%)
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC)...

XBIO : 3.38 (+0.30%)
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer

XBIO : 3.38 (+0.30%)
Xenetic Biosciences: Q3 Earnings Snapshot

Xenetic Biosciences: Q3 Earnings Snapshot

XBIO : 3.38 (+0.30%)
Xenetic Biosciences: Q2 Earnings Snapshot

Xenetic Biosciences: Q2 Earnings Snapshot

XBIO : 3.38 (+0.30%)

Business Summary

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an...

See More

Key Turning Points

3rd Resistance Point 3.49
2nd Resistance Point 3.47
1st Resistance Point 3.42
Last Price 3.38
1st Support Level 3.35
2nd Support Level 3.33
3rd Support Level 3.28

See More

52-Week High 5.20
Fibonacci 61.8% 4.28
Fibonacci 50% 3.99
Fibonacci 38.2% 3.70
Last Price 3.38
52-Week Low 2.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar